This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Center For Disease Control Survey Reports That One In Four Women Choose Permanent Birth Control

According to the recently released 2006-08 National Survey of Family Growth by the Center for Disease Control (CDC), one in four women choose permanent birth control. Conceptus, Inc. (NASDAQ:CPTS) wants women to know that its Essure ® permanent birth control procedure has been gaining in popularity, and is a safe and effective solution used by hundreds of thousands of women worldwide.

In the past, tubal ligation – a surgery that requires cutting into the body, general anesthesia and a hospital stay – was the only permanent birth control option available to women. Since 2002, the Essure permanent birth control procedure has been a solution to this invasive surgery, and many women have chosen Essure over tubal ligation. The Essure procedure can be performed in the comfort of a doctor’s office in minutes; it does not require surgery, general anesthesia, scarring, burning, hormones or slowing down to recover.

Female permanent birth control is used by 16.7%, or 10.3 million women, and male sterilization (vasectomy) is used by the partners of 6.1%, or 3.7 million women.

“From the CDC data, we can infer that when combined, permanent birth control for both men and women is the single most prevalent form of birth control used today,” said Mark Sieczkarek, CEO of Conceptus, Inc.

“When a woman is considering permanent birth control I recommend the Essure procedure," said Dr. Cindy Basinski, a board-certified OB/GYN based in Evansville, Ind. "Women need to be informed about their options, and I'm always glad to bring Essure to their attention. It is proven, easy, and extremely effective. And since it can be performed without anesthesia, Essure allows patients to get back to their family and normal routine quickly.”

Since receiving FDA approval in 2002, the Essure procedure has become a trusted solution for more than 435,000 women and their physicians. The Essure procedure is 99.80 percent effective with zero pregnancies reported in four years of clinical trials, making it the most effective permanent birth control available. To learn more about Essure please visit Essure.com. The National Survey of Family Growth can be found here:  http://www.cdc.gov/nchs/nsfg.htm.

About the Essure Procedure:

The Essure procedure, FDA approved since 2002, is a proven, hormone-free permanent birth control procedure that can be performed in the comfort of a physician’s office in less than 10 minutes without surgery, burning, anesthesia or the risks associated with tubal ligation. Small, flexible inserts are placed in a woman’s fallopian tubes through the cervix without incisions. Over the next three months, the body forms a natural barrier around the micro-inserts to prevent sperm from reaching the egg. Essure is 99.80% effective based on four years of follow up with zero pregnancies reported in clinical trials, making it the most effective form of permanent birth control on the market. The procedure is covered by most insurance plans, and when it is performed in a doctor’s office the cost may be as low as a simple co-pay.

Three months after the Essure procedure, a doctor performs an Essure Confirmation Test to confirm both that the inserts are in place and the fallopian tubes are fully blocked, and that the patient can rely on Essure for permanent birth control. Essure has been proven and trusted by physicians since 2002, with more than 435,000 women worldwide having undergone the Essure procedure.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG
AAPL $126.37 2.53%
FB $83.20 -0.13%
GOOG $552.03 0.67%
TSLA $190.57 3.01%
YHOO $44.95 -0.33%

Markets

DOW 17,976.31 +263.65 1.49%
S&P 500 2,086.24 +25.22 1.22%
NASDAQ 4,947.4410 +56.2220 1.15%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs